Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Behavioral Sciences (Basel, Switzerland)|July 28, 2023
Investigating Latent Interactions between Students' Affective Cognition and Learning Performance: Meta-Analysis of Affective and Cognitive FactorsJian Li, Eryong Xue, Chenchang Li, et al.Lung|January 16, 2024
Elevated Eosinophil Counts in Acute Exacerbations of Bronchiectasis: Unveiling a Distinct Clinical PhenotypeWeixin Chen, Siyi Ran, Chenchang Li, et al.BMC Oral Health|February 24, 2026
TCIRG1+neutrophils: biomarkers of adverse prognosis in tongue squamous cell carcinomaGuoxin Huang, Chenchang Li, Yupeng Wu, et al.ACS Medicinal Chemistry Letters|March 16, 2018
Y08060: A Selective BET Inhibitor for Treatment of Prostate CancerQiuping Xiang, Yan Zhang, Jiaguo Li, et al.Journal of Medicinal Chemistry|June 14, 2021
Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse AgonistXishan Wu, Hui Shen, Yan Zhang, et al.European Journal of Medicinal Chemistry|February 16, 2018
Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancerQiuping Xiang, Chao Wang, Yan Zhang, et al.European Journal of Medicinal Chemistry|May 15, 2018
Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancerXiaoqian Xue, Yan Zhang, Chao Wang, et al.Journal of Medicinal Chemistry|April 10, 2019
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate CancerYan Zhang, Xishan Wu, Xiaoqian Xue, et al.Journal of Medicinal Chemistry|March 24, 2018
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC)Maofeng Zhang, Yan Zhang, Ming Song, et al.Pageof 1